Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain

Core Viewpoint - PharmNovo has received approval from Spanish regulatory authorities to initiate a phase 2a clinical trial for its drug candidate PN6047, aimed at treating neuropathic pain, with plans to expand the study to other EU countries [1][2]. Company Overview - Karolinska Development AB holds a 20% ownership stake in PharmNovo, which is focused on developing innovative medical treatments [5]. - The company specializes in identifying and investing in breakthrough medical innovations in the Nordic region, aiming to create and grow companies that advance these innovations into commercial products [6][8]. Clinical Development - The phase 2a clinical trial will assess the safety and efficacy of PN6047 in patients with neuropathic pain, with patient enrollment expected to start by mid-2026, contingent on securing necessary funding [2]. - The current study is fully aligned with the requirements set by the U.S. FDA, following a successful pre-IND Type B meeting in January 2025 [3]. Drug Candidate Details - PN6047 is a selective delta-opioid receptor agonist (DORA) being developed as a new treatment for complex pain conditions, potentially addressing severe pain without the addiction issues associated with traditional opioids [4][5].